Table 1 displaying patient characteristics
From: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
|  | Variable | Responder (n = 12) | Non-Responder (n = 5) |
|---|---|---|---|
Sex | Male | 9 (75%) | 1 (20%) |
Female | 3 (25%) | 4 (80%) | |
Age (years) | Mean ± SD | 62 ± 5 | 70 ± 5 |
Tumour size | cT1 | 0 (0%) | 0 (0%) |
cT2 | 3 (25%) | 2 (40%) | |
cT3 | 1 (8%) | 0 (0%) | |
cT4 | 8 (67%) | 3 (60%) | |
Nodal status | cN0 | 5 (42%) | 1 (20%) |
cN1 | 3 (25%) | 2 (40%) | |
cN2 | 4 (33%) | 2 (40%) | |
Metastasis | cM0 | 6 (50%) | 1 (20%) |
cM1 | 6 (50%) | 4 (80%) | |
CA19-9 (U/ml) | Median | 621 | 5044 |
IQR | 665 | 1241 | |
CEA (ng/ml) | Median | 3.3 | 38.0 |
IQR | 2.7 | 25.5 | |
First line chemotherapy | FOLFIRINOX | 7 (58%) | 4 (80%) |
gemcitabine based | 5 (42%) | 1 (20%) |